Patents Issued in November 12, 2024
  • Patent number: 12138227
    Abstract: A capsule sealing system comprising: a heating unit for mounting on a capsule filling machine and receiving therein a plurality of filled capsules (FC) from the capsule filling machine, the heating unit comprising a first plate and a second plate spaced apart from each other by at least one biasing means, each plate having a plurality of grooves forming a plurality of circular holes between the plates when abutted to each other against the biasing means, to capture and heat seal each capsule; and an engaging mechanism for abutting the first and second plates against the biasing means.
    Type: Grant
    Filed: May 2, 2020
    Date of Patent: November 12, 2024
    Inventors: Karan Singh, Prakash Deshmukh, Jayesh Naidu
  • Patent number: 12138228
    Abstract: A drug packaging device includes a drug accommodating/dispensing unit that supplies various types of drugs, a drug packaging portion in which a drug supplied from the drug accommodating/dispensing unit is packaged in a packaging sheet, a drug packaging introducing member that drops the drug to be packaged into the packaging sheet in the drug packaging portion), a pooling portion that pools, upstream of this drug packaging introducing member, the drug, and a drug imaging device that captures an image of the drug in the pooling portion. The drug imaging device performs an imaging process of capturing an image of the drug in the pooling portion in a non-backlit state, and an imaging process of capturing an image of the drug in the pooling portion in a backlit state.
    Type: Grant
    Filed: September 3, 2021
    Date of Patent: November 12, 2024
    Assignee: YUYAMA MFG. CO., LTD.
    Inventors: Naoki Koike, Masao Fukada, Ryosuke Fukamori, Thanhxuan Huynh
  • Patent number: 12138230
    Abstract: A pill cutter is provided and has a base, two holders, a driving assembly, and a lid. The two holders are movably mounted on the base and configured to clamp one or multiple pills at the same time. The driving assembly is connected to the two holders and is capable of driving the two holders to move. The driving assembly comprises two wheels and the two wheels are connected to the two holders. The lid is tiltably mounted on the base, and a blade is mounted on the lid and configured to split the pill(s) at the same time. When the two wheels are rotated, the two holders are capable of moving toward each other or away from each other. With the holders driven by the wheels, multiple pills can be clamped by the holders and cut at once, which saves a lot of time.
    Type: Grant
    Filed: April 22, 2022
    Date of Patent: November 12, 2024
    Assignee: E-LINK PLASTIC & METAL INDUSTRIAL CO., LTD.
    Inventor: You Lin Wang
  • Patent number: 12138231
    Abstract: A moisture- and dust-proof lockable press-type spring compartment pillbox is provided. The pillbox includes an upper cover, a lower bottom provided below the upper cover, and a plurality of plastic drawers provided between the upper cover and the lower bottom. An upper end of each plastic drawer is provided with a silicone inner cover. The plastic drawer is slidably provided along an inner side of the lower bottom. A rear end of the plastic drawer is provided with a locking joint. A rear edge of the inner side of the lower bottom is provided with a plurality of lock assemblies that correspond one-to-one with the locking joints on the plurality of plastic drawers. The lock assembly includes a built-in lock pliers for clamping the locking joint when the plastic drawer is pushed into the lower bottom, so as to fix the plastic drawer to the lower bottom.
    Type: Grant
    Filed: March 15, 2024
    Date of Patent: November 12, 2024
    Inventor: Qiang Chen
  • Patent number: 12138232
    Abstract: Described herein are compounds of Formula I: wherein R1-R6 are as described herein, for use in the treatment of a coronavirus infection; a method of inhibiting a coronavirus 3CL protease, by contacting the 3CL protease with a compound of Formula I; as well as methods pharmaceutical composition comprising a compound of Formula I and at least one phospholipid, wherein a weight ratio of the phospholipid(s) to the compound in the composition is in a range of from 10:1 to 1:10. Further described herein is a method of treating a coronavirus infection in a subject in need thereof, by administering to the subject at least one compound that exhibits at least two of: inhibition of an activity of a 3CL protease of the coronavirus; inhibition of inflammation in the subject; and inhibition of autophagy in the subject.
    Type: Grant
    Filed: December 22, 2023
    Date of Patent: November 12, 2024
    Assignee: NLC Pharma Ltd
    Inventor: Dorit Arad
  • Patent number: 12138233
    Abstract: The present disclosure relates to methods of treating idiopathic hypersomnia with oxybate, preferably a mixture of salts of oxybate (a mixed salt oxybate).
    Type: Grant
    Filed: February 22, 2021
    Date of Patent: November 12, 2024
    Assignee: Jazz Pharmaceuticals Ireland Limited
    Inventors: Franck Skobieranda, Dan Chen, Amanda Leigh Sterkel, Cuiping Chen, Patricia Chandler
  • Patent number: 12138235
    Abstract: A method of producing a caffeic acid phenethyl ester loaded microvesicular cancer drug targeting SH-SY5Y neuroblastoma cancer. The method includes seeding a plurality of skin stem cells in a medium; enabling the plurality of skin stem cells in the medium to reach a confluency of 70-80% to be seeded in a plurality of culture plates; preparing a caffeic acid phenethyl ester stock solution by dissolving the caffeic acid phenethyl ester in dimethyl sulfoxide DMSO; performing a microvesicle isolation from specialized skin cells; adding the caffeic acid phenethyl ester into a plurality of microvesicles; and separating the caffeic acid phenethyl ester loaded microvesicles from the caffeic acid phenethyl ester which is free in the solution and not loaded to a microvesicle.
    Type: Grant
    Filed: June 15, 2022
    Date of Patent: November 12, 2024
    Assignee: Yeditepe Üniversitesi
    Inventors: Fikrettin Sahin, Pakize Neslihan Tasli, Oguz Kaan Kirbas, Ezgi Avsar Apdik, Huseyin Apdik
  • Patent number: 12138236
    Abstract: The present invention is directed to compositions comprising N-Acetyl Methyl GABA, methods of preparing N-Acetyl Methyl GABA and compositions including N-Acetyl Methyl GABA, and methods of using N-Acetyl Methyl GABA for instance to improve sleep and control anxiety.
    Type: Grant
    Filed: July 24, 2023
    Date of Patent: November 12, 2024
    Assignee: MBI Distributing
    Inventor: Ned L. Jensen
  • Patent number: 12138237
    Abstract: The present invention is directed to compositions comprising N-Acetyl Methyl GABA, methods of preparing N-Acetyl Methyl GABA and compositions including N-Acetyl Methyl GABA, and methods of using N-Acetyl Methyl GABA for instance to improve sleep and control anxiety.
    Type: Grant
    Filed: July 25, 2023
    Date of Patent: November 12, 2024
    Assignee: MBI Distributing
    Inventor: Ned L. Jensen
  • Patent number: 12138238
    Abstract: The present invention is directed to compositions comprising N-Acetyl Methyl GABA, methods of preparing N-Acetyl Methyl GABA and compositions including N-Acetyl Methyl GABA, and methods of using N-Acetyl Methyl GABA for instance to improve sleep and control anxiety.
    Type: Grant
    Filed: July 26, 2023
    Date of Patent: November 12, 2024
    Assignee: MBI Distributing
    Inventor: Ned L. Jensen
  • Patent number: 12138239
    Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.
    Type: Grant
    Filed: December 6, 2023
    Date of Patent: November 12, 2024
    Assignee: FLAMEL IRELAND LIMITED
    Inventors: Jordan Dubow, Hervé Guillard, Claire Mégret, Jean-François Dubuisson
  • Patent number: 12138240
    Abstract: A method for treatment of cardiac dysfunction comprising administering to a subject in need thereof a therapeutically effective amount of at least one of ANAVEX 2-73 or ANAVEX 19-144 or a pharmaceutically acceptable salt thereof or a combination thereof.
    Type: Grant
    Filed: July 26, 2021
    Date of Patent: November 12, 2024
    Assignee: Anavex Life Sciences Corp.
    Inventor: Christopher U. Missling
  • Patent number: 12138241
    Abstract: Embodiments of the invention are directed to compositions containing cannabinoid, cannabidiol, cannabidiol isomer, or cannabidiol analog and combinations thereof for treating diabetes, and methods for treating diabetes by topically or orally administering compositions containing cannabinoid, cannabidiol, or cannabidiol analog to the patient in need of treatment.
    Type: Grant
    Filed: July 8, 2021
    Date of Patent: November 12, 2024
    Assignee: SHAMAN NATURALS, LLC
    Inventor: Maria Crisler
  • Patent number: 12138242
    Abstract: The present application describes a method of treating neuropathic pain in a patient. The method includes a step of administering a pharmaceutical composition to the patient. The pharmaceutical composition consists of one or more pharmaceutically acceptable excipients, Palmitoylethanolamide (PEA) ranging from 35 to 80% by weight, one or more naturally occurring Fatty Acid Amide Hydrolase (FAAH) Inhibitors ranging from 0.5 to 40% by weight, and optionally a vitamin and/or a co-enzyme. The combination of PEA and the one or more naturally occurring FAAH inhibitors in the administered pharmaceutical composition act synergistically to reduce neuropathic pain in the patient.
    Type: Grant
    Filed: April 19, 2023
    Date of Patent: November 12, 2024
    Assignee: Frimline Private Limited
    Inventors: Ankit Shyam Singh, Vedprakash Mishra, Neelima Tongra
  • Patent number: 12138243
    Abstract: A method for treating a viral disease in a subject comprising administering to said subject a therapeutically effective dose of one or more compounds that bind to fatty acid binding protein FABP4, with compounds described in the specification some having the general formula, Formula I-Formula XII, where W1-W4, Z1-Z4, Z1-Z5, X, Y, n, and R1-R5 are as defined in the claims and description of embodiments. In examples, the ring Z contains Z1-Z4. In other examples, the ring Z contains Z1-Z5.
    Type: Grant
    Filed: December 31, 2021
    Date of Patent: November 12, 2024
    Assignee: CRESCENTA BIOSCIENCES
    Inventors: Emre Koyuncu, Hahn Kim, Gokhan Hotamisligil
  • Patent number: 12138244
    Abstract: A drug for renal disease, the drug including a compound represented by the following Formula (I) as an active ingredient.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: November 12, 2024
    Assignees: SHOWA UNIVERSITY, JI XING PAHRMACEUTICALS HONG KONG LIMITED
    Inventors: Terumasa Hashimoto, Keita Shibata, Kazuo Honda, Koji Nobe
  • Patent number: 12138245
    Abstract: The invention features dosing regimens and pharmaceutical formulations for oral administration of palovarotene. The dosing regimens can reduce heterotopic ossification, reduce the number of flare-ups, and/or reduce the severity of flare-ups in subjects suffering from fibrodysplasia ossificans progressiva.
    Type: Grant
    Filed: April 17, 2024
    Date of Patent: November 12, 2024
    Assignee: Clementia Pharmaceuticals Inc.
    Inventors: Clarissa Desjardins, Donna Roy Grogan, Jeffrey Neal Packman, Mark Harnett
  • Patent number: 12138246
    Abstract: The present disclosure relates to improved methods of treatment with nirogacestat.
    Type: Grant
    Filed: April 2, 2024
    Date of Patent: November 12, 2024
    Assignee: SPRINGWORKS THERAPEUTICS, INC.
    Inventors: Allison Lim, Shinta Cheng, Todd Webster Shearer, Rex Williams, Kristin Patterson
  • Patent number: 12138247
    Abstract: Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.
    Type: Grant
    Filed: March 8, 2024
    Date of Patent: November 12, 2024
    Assignee: BioXcel Therapeutics, Inc.
    Inventors: Vasukumar Kakumanu, David Christian Hanley, Frank Yocca, Chetan Dalpatbhai Lathia, Lavanya Rajachandran, Robert Risinger
  • Patent number: 12138248
    Abstract: Long term storage stable bendamustine-containing compositions are disclosed. The compositions can include bendamustine or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable fluid which can include in some embodiments PEG, PG or mixtures thereof and an antioxidant or chloride ion source. The bendamustine-containing compositions have less than about 5% total impurities, on a normalized peak area response (“PAR”) basis as determined by high performance liquid chromatography (“HPLC”) at a wavelength of 223 nm, after at least about 15 months of storage at a temperature of from about 5° C. to about 25° C.
    Type: Grant
    Filed: April 25, 2024
    Date of Patent: November 12, 2024
    Assignee: Eagle Pharmaceuticals, Inc.
    Inventors: Nagesh R. Palepu, Philip Christopher Buxton
  • Patent number: 12138249
    Abstract: Disclosed herein are methods of treating conditions, which may be associated with elevated levels of eosinophils and/or basophils, with a therapeutically effective amount of dexpramipexole or pharmaceutical acceptable salt thereof.
    Type: Grant
    Filed: March 6, 2023
    Date of Patent: November 12, 2024
    Assignee: Areteia Therapeutics, Inc.
    Inventors: Michael E. Bozik, Gregory Hebrank, Wildon Farwell, Thomas Petzinger, Jr., Steven Dworetzky
  • Patent number: 12138250
    Abstract: 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile, or a pharmaceutically acceptable salt, amorphous form, polymorph form, or pharmaceutical composition (including solid formulations or liquid formulations) thereof and the use thereof for treating diseases and disorders which can be treated with a RET kinase inhibitor, such as RET-associated diseases and disorders, e.g., proliferative disorders such as cancers, including hematological cancers and solid tumors, and gastrointestinal disorders such as IBS are disclosed.
    Type: Grant
    Filed: January 21, 2022
    Date of Patent: November 12, 2024
    Assignee: Loxo Oncology, Inc.
    Inventors: Mark Reynolds, Charles Todd Eary
  • Patent number: 12138251
    Abstract: The present invention provides a pharmaceutical composition for preventing and/or treating a disease characterized by fibrosis of a cell or a tissue, the pharmaceutical composition comprising a compound represented by formula 1 or a salt thereof, and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: January 30, 2020
    Date of Patent: November 12, 2024
    Assignees: SCIENCE FARM LTD., LINK GENOMICS, INC.
    Inventors: Lin Kurahara, Hironobu Ihn, Masami Otsuka
  • Patent number: 12138252
    Abstract: A pharmaceutical composition for prevention or treatment of a disease or disorder characterized by chronic inflammation, with associated angiogenesis and fibrosis, wherein the disease or disorder is selected from the group consisting of rosacea, psoriasis, erythema multiforme, bullous pemphigoid, hereditary hemorrhagic telangiectasia, rheumatoid arthritis, atopic dermatitis, and dermal wound healing. The pharmaceutical composition includes at least one multi-kinase inhibitor selected from the group consisting of axitinib, nintedanib, and lenvatinib.
    Type: Grant
    Filed: December 29, 2020
    Date of Patent: November 12, 2024
    Assignee: AIVIVA BIOPHARMA, INC.
    Inventors: Diane Tang-Liu, Gerald Woodrow DeVries
  • Patent number: 12138253
    Abstract: Provided is a method for preventing, ameliorating, suppressing the progression of, and/or treating a tumor caused by a tumor virus, the method including the step of administering, to a subject, an effective amount of a component that targets a gene product of the tumor virus.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: November 12, 2024
    Assignee: KYOTO UNIVERSITY
    Inventors: Masatoshi Hagiwara, Masahiko Ajiro, Tetsunori Sakamoto
  • Patent number: 12138254
    Abstract: The present invention relates to chronic nightly use of lasmiditan for the prevention of migraine, particularly therapy resistant migraine which is defined herein as migraine refractory to two or more prior monotherapy and/or dual therapy treatment or prevention regimens.
    Type: Grant
    Filed: September 3, 2019
    Date of Patent: November 12, 2024
    Assignee: Eli Lilly and Company
    Inventors: Robert Russell Conley, Gudarz Davar, Kirk Willis Johnson
  • Patent number: 12138255
    Abstract: Pharmaceutical compositions are provided, which comprise cabozantinib or pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient, wherein the inventive compositions exhibit enhanced bioavailability compared to the currently marketed or commercially available formulations. The present invention also provides manufacturing processes thereof and use of the said inventive compositions for the prevention, treatment or prophylaxis of disorders in human patients in need thereof. The present invention relates to oral pharmaceutical compositions of cabozantinib, methods for their administration, processes for their production, and use of these compositions for treatment of diseases treatable by cabozantinib.
    Type: Grant
    Filed: May 5, 2023
    Date of Patent: November 12, 2024
    Assignee: SLAYBACK PHARMA LLC
    Inventors: Sushant Omprakash Dube, Suprit Dilip Saoji, Pankaj Kisan Chatki, Sumitra Ashokkumar Pillai, Girish G. Kore
  • Patent number: 12138256
    Abstract: The present invention relates to the use of (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4?-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid of formula (I), prefer-ably in form of one of its salts or solvates or hydrates, preferably (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4?-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid in form of monohydrate (I) of formula (I-M-I) or (5S)-{[2-(4-carboxyphenyl)ethyl][2-(2-{[3-chloro-4?-(trifluoromethyl)biphenyl-4-yl]methoxy}phenyl)-ethyl]-amino}-5,6,7,8-tetrahydroquinoline-2-carboxylic acid inform of mono hydrate (II) of formula (I-M-II), in the inhalative treatment of cardiopulmonary and pulmonary disorders, such as pulmonary arterial hypertension (P AH), chronic tromboembolic pulmonary hypertension (CTEPH) and pulmonary hypertension (PH) associated with chronic lung disease (PH group 3) such as pulmonary hypertension in chronic obstructive pulmon
    Type: Grant
    Filed: November 10, 2023
    Date of Patent: November 12, 2024
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Eva Maria Becker-Pelster, Hanna Tinel, Michael Hahn, Dieter Lang, Gerrit Weimann, Johannes Nagelschmitz, Lisa Dietz, Soundos Saleh, David Jung, Ildiko Terebesi, Tobias Mundry, Annett Richter, Britta Olenik, Birgit Keil, Bernd Rösler, Peter Fey, Heiko Schirmer, Guido Becker, Clemens Bothe, Helene Faber, Julian Egger, Mark Parry, David Ward, Cecile Vitre
  • Patent number: 12138257
    Abstract: The present invention relates to antimicrobial compositions and more specifically compositions of quinolone carboxylic acid derivatives. These compositions have improved solubility, stability, and tolerability. These compositions are useful for intravenous administration for treating, preventing, or reducing the risk of infection.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: November 12, 2024
    Assignee: MELINTA SUBSIDIARY CORP.
    Inventors: Danping Li, Eric S. Burak, David S. Dresback, Danielle B. Lord
  • Patent number: 12138258
    Abstract: The invention generally relates to solid forms of berberine ursodeoxycholate, and to pharmaceutical compositions, and methods of preparation and therapeutic use thereof. In particular, the invention relates to solid forms of berberine ursodeoxycholate and pharmaceutical compositions thereof useful in treating and/or preventing various diseases or disorders, including metabolic disorders, heart diseases, neurodegenerative diseases and liver diseases.
    Type: Grant
    Filed: February 23, 2021
    Date of Patent: November 12, 2024
    Assignee: SHENZHEN HIGHTIDE BIOPHARMACEUTICAL, LTD.
    Inventors: Meng Yu, Liping Liu, Xinxiang Fu
  • Patent number: 12138259
    Abstract: The present disclosure is directed to a method of combatting opioid dependence in a subject experiencing a depressive episode. The method comprises treating the subject with an opioid agonist whilst managing their depression or depressive disorder using a step-wise interactive process, particularly where the process involves virtual cognitive behavioral therapy comprising a program for self-treatment. The self-treatment program could be embodied as a mobile medical application.
    Type: Grant
    Filed: April 3, 2023
    Date of Patent: November 12, 2024
    Assignee: OREXO AB
    Inventor: Michael John Sumner
  • Patent number: 12138260
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: September 27, 2023
    Date of Patent: November 12, 2024
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 12138261
    Abstract: Compounds and pharmaceutical compositions thereof for inducing apoptosis in a cell expressing Bcl-2 and IP3R and their use in a method for treating neoplastic disorders in a subject.
    Type: Grant
    Filed: January 25, 2022
    Date of Patent: November 12, 2024
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventor: Clark Distelhorst
  • Patent number: 12138262
    Abstract: The invention relates to a method for the manufacture of a compound of Formula I as mentioned above, or a pharmaceutically acceptable salt, acid co-crystal, hydrate or other solvate thereof, said method comprising reacting a compound of the formula II with a compound of the formula III according to the following reaction scheme: wherein A, LG, n and m are as defined in the Summary of the Invention.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: November 12, 2024
    Assignee: NOVARTIS AG
    Inventors: Zhongbo Fei, Gang Lu, Yinbo Wan, Jianhua Wang, Quanbing Wu, Hao Zhang
  • Patent number: 12138263
    Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: November 12, 2024
    Assignees: Relay Therapeutics, Inc., D.E. Shaw Research, LLC
    Inventors: Alexander M. Taylor, Fabrizio Giordanetto, Jack Benjamin Greisman, Paul Maragakis, Heike Schoenherr
  • Patent number: 12138264
    Abstract: The present Invention relates to pharmaceutical compositions of (3S, 11aR)-N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide, useful in the treatment or prevention of Human Immunodeficiency Virus (HIV) infections.
    Type: Grant
    Filed: May 31, 2024
    Date of Patent: November 12, 2024
    Assignee: ViiV Healthcare Company
    Inventors: Deepak B. Mundhra, Rennan Pan
  • Patent number: 12138265
    Abstract: Provided herein are heteroaryl compounds, for example, a compound of Formula I or IA, and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, ameliorating, or preventing one or more symptoms of a disorder, disease, or condition mediated by a casein kinase 1 (CK1), an interleukin-1 receptor associated kinase (IRAK1), or a cyclin-dependent kinase 9 (CDK9).
    Type: Grant
    Filed: January 25, 2023
    Date of Patent: November 12, 2024
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd
    Inventors: Irit Snir-Alkalay, Joseph P. Vacca, Yinon Ben-Neriah
  • Patent number: 12138266
    Abstract: The present invention relates to preparations of folate salts and their topical use for the treatment of epithelial tissue irritations and skin disorders.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: November 12, 2024
    Assignee: Aprofol AG
    Inventors: Martin Ulmann, Gerd Wiesler, Hans Dutler
  • Patent number: 12138267
    Abstract: Disclosed in certain embodiments is a method of treating respiratory depression modulated by a non-opioid agent comprising administering, to a patient in need thereof, an effective amount of a compound selected from Formula (I) as disclosed herein.
    Type: Grant
    Filed: November 2, 2022
    Date of Patent: November 12, 2024
    Assignee: Enalare Therapeutics Inc.
    Inventors: Joseph Pergolizzi, Thomas Miller, Alfred Schweikert
  • Patent number: 12138268
    Abstract: The present invention generally relates to the transdermal delivery of various compounds. In some aspects, transdermal delivery may be facilitated by the use of a hostile biophysical environment. One set of embodiments provides a composition for topical delivery comprising a phosphodiesterase type 5 inhibitor and/or a salt thereof, and optionally, a hostile biophysical environment and/or a nitric oxide donor. In some cases, the composition may be stabilized using a combination of a stabilization polymer (such as xanthan gum, KELTROL® BT and/or KELTROL® RD), propylene glycol, and a polysorbate surfactant such as Polysorbate 20, which combination unexpectedly provides temperature stability to the composition, e.g., at elevated temperatures such as at least 40° C. (at least about 104° F.), as compared to compositions lacking one or more of these.
    Type: Grant
    Filed: April 18, 2023
    Date of Patent: November 12, 2024
    Assignee: Strategic Science & Technologies, LLC
    Inventor: Eric T. Fossel
  • Patent number: 12138269
    Abstract: Methods of treating patients suffering from or exhibiting symptoms of mental, behavioral, and/or cognitive disorders with azelastine or a pharmaceutically acceptable salt of azelastine are disclosed.
    Type: Grant
    Filed: May 17, 2023
    Date of Patent: November 12, 2024
    Assignee: LA PharmaTech Inc.
    Inventors: Jianmin Wang, Geping Cui
  • Patent number: 12138270
    Abstract: A contraceptive regimen that provides for a reduced level of estrogen. The contraceptive regimen can be used for the treatment of symptoms associated with endometriosis or fibroids.
    Type: Grant
    Filed: September 23, 2021
    Date of Patent: November 12, 2024
    Assignee: Millicent Pharma Limited
    Inventors: Roger M. Boissonneault, Ryan Loughlin
  • Patent number: 12138271
    Abstract: Stable pharmaceutical compositions are provided, comprising a pharmaceutically effective amount of testosterone or a pharmaceutically acceptable ester thereof, a pharmaceutically acceptable oil vehicle, and a stabilizing amount of benzyl alcohol, for example, about 1% to 3% weight/volume of benzyl alcohol. The present invention also provides a process for stabilizing testosterone-containing pharmaceutical compositions by ageing them at a temperature of about 20° C. to about 60° C. for at least 48 hours, e.g., prior to secondary packing and labeling. These compositions were stable over the shelf life of the product, without exhibiting crystal formation, even upon storing at temperatures of about 2° C. to about 8° C. Other aspects of the invention relate to methods for making such pharmaceutical compositions and methods of using such pharmaceutical compositions for hormone replacement therapy, e.g.
    Type: Grant
    Filed: April 12, 2023
    Date of Patent: November 12, 2024
    Assignee: SLAYBACK PHARMA LLC
    Inventors: Umangi K. Soni, Prem Prakash Singh, Hanimi Reddy Bapatu, Praveen Kumar Subbappa, Ajay Kumar Singh
  • Patent number: 12138272
    Abstract: Provided herein are methods for treating at least one symptom of ALS in a subject who has received a first dosage of BSEP inhibitor, the method including administering to the subject a composition comprising a bile acid or a pharmaceutically acceptable salt thereof and a phenylbutyrate compound, monitoring the subject for response to the B SEP inhibitor, and administering a second dosage of the BSEP inhibitor, wherein the second dosage is less than the first dosage.
    Type: Grant
    Filed: May 12, 2022
    Date of Patent: November 12, 2024
    Assignee: Amylyx Pharmaceuticals, Inc.
    Inventors: Joshua Cohen, Justin Klee
  • Patent number: 12138273
    Abstract: Sustained-release abiraterone prodrug formulations, methods, and kits for parenteral administration to a subject having a sex hormone-dependent benign or malignant disorder such as prostate cancer, a syndrome due to androgen excess, and/or a syndrome due to glucocorticoid excess such as hypercortisolemia.
    Type: Grant
    Filed: January 19, 2023
    Date of Patent: November 12, 2024
    Assignee: PROPELLA THERAPEUTICS, INC.
    Inventors: Matthew J. Sharp, William R. Moore, Jr.
  • Patent number: 12138274
    Abstract: Compositions and methods for the treatment of peripheral artery disease and cardiopulmonary diseases or disorders are provided. In accordance with the instant invention, methods of inhibiting, treating, and/or preventing peripheral artery disease or symptoms associated therewith are provided. In a particular embodiment, the methods inhibit, treat, and/or prevent claudication associated with peripheral artery disease.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: November 12, 2024
    Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
    Inventors: Hanjun Wang, Dong Wang, Thomas Nicholas, Michael Lankhorst, Steven Lisco, Irving Zucker, Lie Gao, Juan Hong
  • Patent number: 12138276
    Abstract: Disclosed are novel halogenated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced using a biosynthetic system which comprises cells comprising a psilocybin biosynthetic enzyme complement.
    Type: Grant
    Filed: May 6, 2024
    Date of Patent: November 12, 2024
    Assignee: Enveric Biosciences Canada Inc.
    Inventors: Jillian M. Hagel, Peter J. Facchini
  • Patent number: 12138277
    Abstract: Oligosaccharides are for use in the treatment of neurodegenerative diseases of the central nervous system, in particular Parkinson's disease, and to pharmaceutical compositions including one or more of the oligosaccharides.
    Type: Grant
    Filed: July 11, 2019
    Date of Patent: November 12, 2024
    Assignee: UNIVERSITA' DEGLI STUDI DI MILANO
    Inventors: Sandro Sonnino, Elena Chiricozzi
  • Patent number: 12138278
    Abstract: The disclosure provides a topical gel formulation comprising 1-1.5 wt. % clindamycin phosphate, 2.5-3.5 wt. % benzoyl peroxide, and 0.1-0.2 wt. % adapalene, in combination with a gelling agent, a polyhydric alcohol, and water, useful in treating inflammatory skin conditions, including acne, together with methods of making and using the same.
    Type: Grant
    Filed: April 18, 2024
    Date of Patent: November 12, 2024
    Assignee: BAUSCH HEALTH IRELAND LIMITED
    Inventors: Varsha Bhatt, Radhakrishnan Pillai, Arturo Angel
  • Patent number: 12138279
    Abstract: Provided are aptamers and aptamer compositions and particularly, although not exclusively, to a bi-specific aptamer capable of binding a tumor cell antigen and an immune cell surface protein.
    Type: Grant
    Filed: November 29, 2021
    Date of Patent: November 12, 2024
    Assignee: City of Hope
    Inventors: John J. Rossi, Sorah Yoon, Nagy Habib, Piotr Marek Swiderski